Payer Strategy & Market Dynamics
Expert articles and analysis related to payer strategy & market dynamics.
AI Summary — Last 30 Days
Over the past 30 days, several developments have reinforced that U.S. value-based care strategy is actively shifting to address persistent market misalignments, integration challenges, and expansion of targeted population health initiatives. The BALANCE program—launched by CMMI in late 2025—continues to reshape Medicare Advantage (MA) dynamics by broadening coverage for GLP-1 obesity therapies while intensifying selection risk management for plans, signaling CMS’s willingness to test bold benefit designs under new payment models see: BALANCE: Evidence from Recent MA Data. At the same time, finalized updates to the Part D risk adjustment model for 2027 will create sharper financial distinctions between MA-PDs and stand-alone PDPs, with significant implications for plan payment structures and downstream network strategy see: 2027 Part D Risk Adjustment Changes. ACO consolidation and expansion also continue, as major systems like WellSpan Health invite new provider organizations into their risk-bearing frameworks, underscoring the competitive imperative to scale in the evolving VBC landscape. Persistent structural tensions remain—particularly around defensive medicine, the adequacy of current payment design, and the practical integration of digital and novel therapies into value-oriented contracts—highlighting that VBC’s challenges stem not from its underlying
Related Articles
STAT+: White House digs in on ‘most-favored nation’ drug pricing despite Congress’ cool reception
Despite a cool reception from Congress, the White House is looking to intensify its pressure campaign on lawmakers to pass a “most-favored nation" drug pricing bill.
STAT+: Asthma patients suffered as GSK pursued ‘egregious’ price hikes, senator says
After GSK replaced a popular asthma inhaler with an identical product at a higher price, families reported substantial financial and treatment problems, according to a new report.
Medicare Drug Price Negotiation: What Can We Learn From the 2027 Prices and Their Justifications?
Medicare Drug Price Negotiation: What Can We Learn From the 2027 Prices and Their Justifications? Health Affairs
15 drugs selected for Medicare negotiation program
15 drugs selected for Medicare negotiation program Becker's Hospital Review
Reimagining Prior Authorization: Increasing Transparency for Stakeholders
Reimagining Prior Authorization: Increasing Transparency for Stakeholders Fierce Healthcare
IRA Litigation: Pharma’s Failed Challenges To Medicare Drug Pricing
IRA Litigation: Pharma’s Failed Challenges To Medicare Drug Pricing Health Affairs
Panel: AI can improve prior authorization in healthcare but won’t solve all the issues
New approaches to prior authorization are crucial to improve a process that remains essential to supporting healthcare quality, according to a subject matter expert. “Prior auth exists because there’s...
Poll: Public Worries About Prescription Drug Costs Reach New High; Most Across Political Parties Want Government to Do More to Regulate Prices
As the Trump administration promotes its new TrumpRx website and other efforts to lower prescription drug prices, a growing majority of the public worries about being able to afford prescription drugs...
Public Views on Prescription Drug Costs: Regulation, Affordability and TrumpRx
Amid the Trump administration's focus on lowering prescription drug costs, including its new TrumpRx website, KFF's Health Tracking Poll finds that most Americans (59%) are worried about affording pre...
Families Scramble To Pay Five-Figure Bills as Clock Ticks on Promised Preauthorization Reforms
Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, which often requires patients or their doctors to seek preapproval from insurers be...